comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-03 05:01:21 - browse：525

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

WSS

AstraZeneca challenges Medicare drug negotiation program

Departing Stanford president retracts two papers

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Why more medical students aren't specializing in primary care

Apellis safety probe of eye disease drug centers on injection needle

entertainment

comprehensive

leisure time

In age of alternative facts, a scholarly course on calling out crap

Medicare coverage of Wegovy, once blocked, now looks possible

Virginia high school admissions case could be legal follow

What AAP's gender

Hepatitis C has a cure — but many Americans still lack access to it

Change Healthcare outage fallout shows need for new oversight

23andMe had bad news about my health. I wish a person had delivered it

FDA advisers back CAR

Heart attack and stroke risk calculators need revising

Winners, losers from Medicare’s list of drugs subject to price talks

Wikipedia

Apellis safety probe of eye disease drug centers on injection needle

NYU Langone launches private ChatGPT for its health care data

How to save health care price transparency rules

What AAP's gender

Why depression after traumatic brain injury is distinct

Amid AI frenzy, a top HHS official's quest to create safeguards

Wikipedia

leisure time

hotspot

hotspot